Publication | Open Access
Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
89
Citations
0
References
2019
Year
Checkmate 358Cervical CancerMedicineCancer ManagementGynecologyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyGynecology Oncology
No additional data available for this publication yet. Check back later!